27th – 29th January, 2026 | Berlin, Germany
www.mrnabased-therapeutics-europe.com

REGISTER BY FRIDAY, 17TH OCTOBER TO SAVE UP TO €900

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

5th Annual

mRNA-Based Therapeutics Summit EUROPE

Advancing mRNA Technology & Innovation Across Therapeutic Applications for Regulatory Approval

Boosting mRNA Potential for Therapeutics, Gene-Editing & Vaccine Applications With Scalable Design, Guided Delivery, & Validated Clinical Safety

Expert Speakers Include:

Andreas Kuhn
Senior Vice President
RNA Biochemistry & CMC Development
BioNTech

Maren Von Fritschen
Head of Regulatory Policy Europe
Moderna

Thomas Langenickel
Chief Medical Officer
Ethris

Salman Mustfa
Senior Scientist
AstraZeneca

Steve Pascolo
Senior Scientist
University Hospital of Zurich

Sabine Maamari
Chief Operating Officer
Avocet Bio

Proud to Partner With:

Recipharm SARTORIUS Vazyme Roche ELEGEN intertek

+44 (0)20 3141 8700 info@hansonwade.com
www.mrnabased-therapeutics-europe.com World RNA Events Series
hansonwade

Welcome to 5th mRNA Based Therapeutics Summit Europe

5th Annual mRNA-Based Therapeutics Summit EUROPE

27th – 29th January, 2026 | Berlin, Germany

Accelerate the Next Generation of mRNA Therapeutics Through Smarter Design, Innovative Delivery, Scalable Manufacturing, & Proven Clinical Safety

With BioNTech's $1.25B acquisition of CureVac, the EMA and MHRA issuing clear guidelines on mRNA development, and the milestone of Baby KJ receiving the world's first personalised CRISPR therapy, Europe is proving that the mRNA field has entered a new phase of maturity. These milestones demonstrate growing investor confidence, regulatory clarity, and clinical translation signs that **after years of turbulence, the field has regained stability and is now accelerating toward novel therapeutic and gene editing applications** that could transform patient outcomes.

The **5th mRNA-Based Therapeutics Summit Europe** returns to Berlin with a refreshed focus to cover the end-to-end of new mRNA products overcoming key challenges from **sequence design, targeted LNP and non-viral cargoes to accelerated manufacturing enabling progress of potent, stable and scalable mRNA products into the clinic and beyond**. Uniting leaders from biopharma, regulatory experts and solution providers from across Europe, UK and Asia, this year's agenda will encompass a **gene editing focus day**, two dedicated tracks on **pre-clinical and clinical development** and **technology innovation and manufacturing**, dive into **fresh investor-focused sessions** tackling today's hottest funding challenges, and gain clarity on **evolving regulatory pathways** shaping mRNA's future.

Built with biopharmaceutical insights from **BioNTech**, **Divincell**, **Roche**, **Moderna**, **Ethris**, and more, join **150+ senior mRNA experts** from all stages of development, from R&D to CMC, for an unrivalled learning, networking, and partnering opportunity to advance mRNA technology and innovation across modalities for a commercial product. Not only will you gather technical innovation insight, but strategic business insights and investor perspectives will also be covered.

What Our Speakers have to Say

"The most relevant mRNA meeting in the industry that provides access to key opinion leaders and to gain insights into the last advance of mRNA therapeutics"

Past Attendee, Senior Scientist, Almirall

"The best mRNA conference I have attended. Excellent conference to meet the leaders in the field. The scientific program, the exchange and the networking were unrivalled"

Past Attendee, CEO, DivinCell

Key Highlights Include:

Engineering next generation cas9 variants that are **expanding precision, efficiency, and safety in gene editing** applications with **AstraZeneca**

Advancing emerging lipid and polymer systems designed for non-hepatic targeting to **enable mRNA applications in hard-to-reach tissues** with **Divincell**

Unlock strategies to **achieve efficient local delivery of mRNA to hard-to-reach musculoskeletal tissues**, helping you de-risk preclinical development and accelerate translation into regenerative therapies with **Ethris**

Leveraging the advantages of **chemically synthesised mRNA to test new nucleotide modifications** and ease the production of individualsed anticancer vaccines with **University Hospital of Zurich**

Gain clarity on how regulators are adapting **frameworks beyond vaccines, from oncology-focused and personalised mRNA therapies** to sandbox and platform approaches that can accelerate your candidate's path from concept to clinic with **Moderna** & **BioNTech**

Gain insider perspectives on **what makes an mRNA platform fundable in 2026**, with investors revealing how to **de-risk pipelines, prove value beyond vaccines, and secure strategic partnerships** in a competitive funding landscape with **Provisio Ventures** & **Innosuisse**

Gene Editing in Focus, Therapeutics in Action: The Evolving mRNA Landscape

5th Annual mRNA-Based Therapeutics Summit EUROPE

27th – 29th January, 2026 | Berlin, Germany

How can mRNA unlock safer, transient gene editing?

With Cas9 engineering advancing, delivery systems evolving, and regulators weighing in, the intersection of mRNA and gene editing is opening bold new therapeutic frontiers. From oncology to rare disease, explore the platforms, strategies, and case studies driving the next generation of therapies at the **Gene Editing Focus Day**.



On the Programme: Disease Areas & Key Players

Respiratory

ETHRIS · Cyberna · Pantherna Therapeutics · AstraZeneca

Oncology

DIVINCELL · moderna · GENEVATION LTD · ABOGEN · altamira therapeutics · circio · BIONTECH · AstraZeneca

Infectious Diseases

moderna · ABOGEN · circio · BIONTECH · AstraZeneca

Rare Diseases

moderna · Cyberna · circio · AstraZeneca

Cardiovascular / Metabolic

AstraZeneca

Autoimmune Diseases

moderna · ABOGEN · altamira therapeutics

Your Expert Speakers

BioPharma:

Bo Ying
Chief Executive Officer
AboGen

Covadonga Paneda
Chief Operating Officer
Altamira Therapeutics

Salman Mustfa
Senior Scientist
AstraZeneca

Sabine Maamari
Chief Operating Officer
Avocet Bio

Annie Sabbah
Chief Technology Officer
Barcode Nanotech

Andreas Kuhn
Senior Vice President
RNA Biochemistry & CMC Development
BioNTech

Kirsten Nespithal
Director Safety Lead Risk Management
BioNTech

Ruben Rizzi
Senior Vice President, Global Regulatory Affairs
BioNTech

Victor Levitsky
Chief Scientific Officer
Circio

Pengbo Guo
Partner
CybernaX Bio

Gilles Divita
Chief Executive Officer
Divincell

Anais Depaix
Advanced Senior Scientist
Eleven Therapeutics

Thomas Langenickel
Chief Medical Officer
Ethris

Prasun Chakraborty
Founder, Innovator & Chief Executive Officer
Genevation

Maren Von Fritschen
Head of Regulatory Policy Europe
Moderna

Ansgar Santel
Chief Executive Officer
Pantherna Therapeutics

Christine Duthoit
Chief Executive Officer & Chief Scientific Officer
RNAlead

Academics:

Regina Bleul
Head of Nanomedicine Group
Fraunhofer

Sandy Tretbar
Group Leader
Fraunhofer

Roland Brock
Professor of Biochemistry, Group Leader Targeted Nanomedicines
Radboud University Medical Center

Your Expert Speakers

Simone Carneiro
Group Leader, LMU Munich – Ludwig-Maximilians
Universität MünchenLMU

Steve Pascolo
Senior Scientist
University Hospital of Zurich

Giovanni Tosi
Professor
University of Modena & Reggio Emilia

Thomas Moore
Assistant Professor
University of Napoli Federico

Philippe Menasché
Professor of Thoracic & Cardiovascular Surgery
University of Paris-Saclay

Marcos Garcia-Fuentes
Professor
University of Santiago de Compostela

Investor & Research Networks:

Siham Ceballos
Medical Affairs & Innovation Expert
Innosuisse

Maciej Drożdż
Former VC Investor, Founder & CEO
MiMo Biotech

Marek Kozlowski
Venture Capital, Life Science & Cleantech Professional
NRW.BANK

Ilya Vensky
General Partner
Provisio Ventures

Michel Baijot
Chairman
White Fund

> "Each section provided relevant insights, and the panel discussions sparked strong in-depth conversations about emerging trends in mRNA"
>
> **Past Attendee, Principal Scientist, Sail Biomedicines**

> "I enjoyed the selection of comprehensive topics focused on mRNA, some topics, such as investment, are rarely covered by other conferences"
>
> **Past Attendee, Associate Director, Tessera Therapeutics**

Gene Editing Focus Day
Tuesday 27th January, 2026

9.00 **Check In & Morning Coffee**

9.50 **Chair's Opening Remarks**

Redefining the Regulatory Landscape for mRNA-Enabled Gene Editing to Advance Clinical Approvals

Maren Von Fritschen
Head of Regulatory Policy Europe
Moderna

10.00 **Navigating Global Regulatory Pathways for mRNA-Based Gene Editing to Accelerate Clinical Translation & Reduce Approval Risk**

- Compare how EMA, FDA, and MHRA approach transient mRNA-based editing tools versus permanent genome modifications
- Understand classification and risk-based assessment challenges for mRNA-delivered editors (e.g., ATMP designation)
- Learn how early regulator engagement can de-risk trial design, accelerate timelines, and improve approval outcomes

10.30 **Roundtable Discussion: Evaluating RNA Versus DNA in Gene Editing to Improve Safety Profiles & Align With Regulatory Expectations**

- Examine how modality choice influences safety, efficacy, and scrutiny in clinical development
- Explore competitive advantages of RNA over DNA platforms across specific indications and cell types
- Align modality selection with CMC feasibility, delivery strategy, and reimbursement potential

11.00 **Morning Break & Networking**

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA field and establish meaningful business relationships to pursue for the rest of the conference

Optimising CMC & Construct Design for mRNA-Enabled Gene Editing to Accelerate Therapies to Clinic

Salman Mustfa
Senior Scientist
AstraZeneca

11.30 NEW DATA **Engineering Next-Generation Cas9s to Advance Rare Disease Therapy Portfolio**

- Explore how engineered Cas9 variants are expanding precision, efficiency, and safety in gene editing applications
- Review strategies for tailoring Cas9 platforms to address the unique challenges of rare disease indications
- Learn from case studies on building a diversified rare disease pipeline through Cas9-based therapeutic development

Maciej Drożdż
Former VC investor, founder & CEO
MiMo Biotech

12.00 NEW DATA **From Vaccines to Vision: Unlocking mRNA's Next Clinical Success**

- Learning from vaccines: Exploring how mRNA's transient biology is not a drawback but an asset
- Building on innovation: Reviewing how advances in mRNA topologies, stability, and delivery systems are expanding what mRNA can achieve
- Why Ophthalmology?: Discussing how eye diseases demand localized, adjustable, and repeatable therapies, exactly where transient, programmable mRNA expression can deliver disease-modifying therapies or cures

12.30 **Lunch & Networking**

Gene Editing Focus Day
Tuesday 27th January, 2026

Choosing the Right mRNA Delivery & Platform to Unlock Clinical Success & Long-Term Therapeutic Impact

Giovanni Tosi
Professor
University of Modena & Reggio Emilia

13.30 **Optimising Gene Editing Delivery Technologies to Achieve Precise Targeting, Enhance Manufacturability & Accelerate Clinical Translation**

- Address manufacturing and CMC challenges for ligand-directed and next-gen formulations
- Review a nanomedicine platform for production and application in therapy
- Gain insights from case studies on tissue-specific delivery in rare diseases, cancer and CNS diseases

Pengbo Guo
Partner
CybernaX Bio

14.00 **Innovative Delivery Systems Enabling mRNA-Mediated Gene Editing in the Lung**

- Explore how novel delivery platforms are overcoming biological and anatomical barriers to target lung tissue effectively through inhalation route
- Understand the potential of combining mRNA technology with next-generation carriers to achieve precise gene editing in pulmonary indications for diseases like PCD and cystic fibrosis
- Review emerging preclinical data showcasing safety, efficiency, and translational promise for respiratory gene editing therapies

Sabine Maamari
Chief Operating Officer
Avocet Bio

14.30 NEW DATA **RNA Editing in the Lung: Programmable Nucleases & Next-Gen Inhaled Delivery for Respiratory Disease**

- Exploring next-generation RNA modalities from programmable nucleases to emerging enzyme systems for therapeutic use in the lung
- Case study: leveraging a Cas13 platform to counter respiratory viral infections
- Designing inhalable delivery vehicles for safe, efficient deposition throughout the airways

15.00 **Chair's Closing Remarks**

15.10 **End of Gene Editing Focus Day**

> "Every session was designed with the necessary topics for current and future mRNA-based therapeutics"
>
> **Past Attendee, Chief Scientific Officer, Aston Science**

Conference Day One
Wednesday 28th January, 2026

7.10 **Check In & Morning Coffee**

Michel Baijot
Chairman
White Fund

8.20 **Chair's Opening Remarks**

Unlocking the Next Chapter of mRNA Therapeutics by Expanding Indications Enhancing Delivery & Advancing Novel RNA Modalities

Gilles Divita
Chief Executive Officer
Divincell

8.30 **Advancing Targeted Delivery & Respiratory Formulations to Enable mRNA Applications in Hard-to-Reach Tissues**

- Exploring advances in organ-specific mRNA delivery, including inhalation, intranasal, and systemic routes
- Examining emerging lipid and polymer systems designed for non-hepatic targeting
- Review case studies and clinical updates from respiratory and extrahepatic mRNA programmes

9.00 **Presentation Reserved for ReciPharm**

Marcos Garcia-Fuentes
Professor
University of Santiago de Compostela

9.30 NEW DATA

Polymeric Delivery Systems for mRNA Demonstrating Translational Potential With *In Vivo* Case Studies

- Explore how polymer-based delivery systems compare to LNPs in terms of stability, targeting, and immunogenicity
- Review *in vivo* data showcasing the performance of polymeric carriers in delivering mRNA to specific tissues
- Understand the implications of polymeric delivery platforms for expanding mRNA applications beyond vaccines

10.00 **Morning Break & Speed Networking**

Join our speed networking session tailored for mRNA experts, like yourselves, to connect with industry peers and facilitating rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections among mRNA experts and stakeholders.

Track A: Pre-Clinical & Clinical Development

Follow the journey from early discovery to first-in-human trials, uncovering how smarter pre-clinical models and clinical strategies are accelerating safe, effective mRNA therapies to patients

Chair: Michel Baijot, Chairman, **White Fund**

11.00 **Advancing mRNA-LNP Technology to Enable Safer & More Effective CAR Cell Therapies**

- Explore how mRNA-LNP platforms enhance the precision and safety of CAR cell engineering
- Review preclinical advances demonstrating improved efficacy and reduced toxicity in CAR-based therapies
- Understand the translational potential of transient mRNA delivery to overcome current limitations in cell therapy

Sandy Tretbar, Group Leader, **Fraunhofer IZI**

NEW DATA

Track B: Technology Innovation & Manufacturing

Explore the breakthroughs in mRNA design, delivery systems, and scalable manufacturing that are transforming innovation into reliable, clinic-ready products

Chair: Andreas Kuhn, Senior Vice President RNA Biochemistry & CMC Development, **BioNTech**

11.00 **Optimising mRNA Architecture to Improve Translation Efficiency Stability & Manufacturability at Scale**

- Explore how modifications to UTRs, polyA tails, and 5' capping structures impact expression and translational fidelity
- Learn from case studies optimising non-coding elements to improve stability and protein yield across platforms
- Understand the design principles behind scalable constructs that remain compatible with standardised GMP production

Anais Depaix, Advanced Senior Scientist, **Eleven Therapeutics**

NEW DATA

Conference Day One
Wednesday 28th January, 2026

11.30 Presentation Reserved for Sartorius BIA Separations

SARTORIUS

11.30 Presentation Reserved for Vazyme

Vazyme™

12.00 Tumour-on-a-Chip Systems to Advance Targeted LNP Delivery for mRNA Therapeutics

- Explore how tumour-on-a-chip platforms provide physiologically relevant models to test LNP targeting and efficacy
- Review case studies demonstrating improved predictability of delivery outcomes compared to conventional *in vitro* assays
- Understand how these systems accelerate candidate optimization and reduce translational risks in oncology applications

Roland Brock, Professor of Biochemistry, Group Leader Targeted Nanomedicines, **Radboud University Medical Center**

NEW DATA

12.00 Developing Scalable Screening Technologies to Accelerate LNP Design from Bench to Bedside

- Explore high-throughput screening innovations that streamline the identification of optimal LNP formulations
- Learn how scalable platforms enable efficient transition from discovery to clinical-grade manufacturing
- Understand how technology transfer strategies are bridging preclinical development with clinical translation

Regina Bleul, Head of Nanomedicine Group, **Fraunhofer ICT-IMM**

NEW DATA

12.30 Advancing Local mRNA Delivery for Bone & Tendon Regeneration

- Explore preclinical strategies that enable efficient local delivery of mRNA to hard-to-reach musculoskeletal tissues such as bone and tendon
- Learn how pharmacology package completion supports safety, efficacy, and translational readiness for regenerative indications
- Understand the implications of localised delivery on reducing systemic exposure while enhancing therapeutic outcomes in tissue repair

Thomas Langenickel, Chief Medical Officer, **Ethris**

NEW DATA

12.30 Unlocking the Potential of Chemically Synthesised mRNA

- Explore how chemical synthesis is overcoming traditional *in vitro* transcription bottlenecks
- Understand the potential advantages of chemically synthesised mRNA to test new nucleotide modifications and ease the production of individualised anticancer vaccines
- Learn from emerging preclinical and translational case studies where chemically synthesised mRNA is expanding therapeutic opportunities
- Identify issues and potential solutions for the use of chemical synthesis to make mRNAs

Steve Pascolo, Senior Scientist, **University Hospital of Zurich**

NEW DATA

13.00 Lunch & Networking

14.00 Optimising *In Vivo* Delivery & Dosing Strategies to Maximise mRNA Therapeutic Efficacy & Safety

- Comparing systemic vs local delivery strategies for achieving tissue-specific expression
- Examining how lipid type, ionisable components, and dosing schedule impact safety and immunogenicity
- Reviewing preclinical to clinical case studies where formulation or dosing adjustments significantly impacted trial outcomes

Ansgar Santel, Chief Executive Officer & Head of Translational Research & Alliance Management, **Pantherna Therapeutics**

NEW DATA

14.00 Expanding mRNA Therapeutic Horizons to Unlock New Targets Tissues & Indications Beyond Infectious Disease

- Exploring FlashRNA®: A disruptive RNA delivery technology for next-generation therapies
- Discovering how mRNA is being applied to oncology, cardiovascular disease, and rare genetic conditions
- Learning from companies breaking away from the vaccine narrative to pursue non-infectious targets

Christine Duthoit, Chief Executive Officer -Chief Scientific Officer, **RNAlead**

14.30 mRNA Based Therapy in Heart Failure

- Discussing advances in mRNA applications for heart failure
- Outlining delivery strategies to target cardiac tissue
- Exploring pathways to clinical translation and approval

Philippe Menasche, Professor of Thoracic & Cardiovascular Surgery, **University of Paris Descartes**

NEW DATA

14.30 High-Throughput Nanoformulation Screening to Accelerate R&D & De-Risk Development

- Rapidly evaluate diverse nano formulations to identify optimal candidates early
- Streamline delivery design with data-driven screening approaches
- Minimise late-stage failures by de-risking formulation decisions in preclinical R&D

Thomas Moore, Assistant Professor | RTDb in the Department of Pharmacy, **Università degli Studi di Napoli Federico II**

Conference Day One
Wednesday 28th January, 2026

5th Annual mRNA-Based Therapeutics Summit EUROPE
27th – 29th January, 2026 | Berlin, Germany

15.00 Poster Session & Afternoon Break

This poster session is your go-to session to obtain competitive insights and present your most innovative work to mRNA thought leaders and stakeholders. For more information or to submit your abstract, please email info@hansonwade.com

Fueling the Future of mRNA Through Smart Capital & Strategic Collaboration

From billion-euro megadeals to targeted niche investments, Europe's mRNA landscape is surging. BioNTech's $1.25B acquisition of CureVac and Cipla's €3M boost for Ethris GmbH are reshaping the competitive and therapeutic landscape. These landmark moves set the stage for critical conversations in this session on how strategic capital and collaboration can unlock the next wave of mRNA innovation.

16.00 Panel Discussion: De-Risking mRNA Innovation to Attract Investment & Partnerships in a Post-Vaccine Era

- What makes an mRNA therapeutic platform fundable in 2026? What clinical and strategic proof do venture capitals want to see?
- How are biotech leaders navigating delivery licensing limitations, high COGS, and regulatory uncertainty to stay attractive to partners?
- Are non-US trial strategies, earlier pharma engagement, or new reimbursement models the key to investor re-engagement?

Siham Ceballos
Medical Affairs & Innovation Expert
Innosuisse

Marek Kozlowski
Venture Capital, Life Science & Cleantech Professional
NRW.BANK

Maciej Drożdż
Former VC investor, founder & CEO
MiMo Biotech

Ilya Vensky
General Partner
Provisio Ventures

16.30 Reviving Investor Confidence in mRNA by Proving Clinical Value Beyond Vaccines & Building De-Risked Development Plans

- Identifying the clinical and strategic proof points investors expect before committing capital especially in oncology and rare disease
- Learning how to differentiate from vaccine legacy perception and position your platform for long-term, non-pandemic relevance
- Understanding the importance of having a clear development and reimbursement roadmap from day one, not post-funding

Michel Baijot
Chairman
White Fund

17.00 Chair's Closing Remarks

17.10 End of Conference Day One

> "An incredibly engaging conference thanks to the high quality of the content, the diversity of perspectives, and the forward-looking focus of the discussions"
>
> **Past Attendee, Director Regulatory Affairs, Moderna**

Conference Day Two
Thursday 29th January, 2026

8.00 **Check In & Morning Coffee**

8.50 **Chair's Opening Remarks**

Redefining Regulatory Pathways for Next-Generation mRNA to De-Risk & Fast Track mRNA Innovation

Ruben Rizzi
Senior Vice President
Global Regulatory Affairs, BioNTech

9.00 **Creating Regulatory Pathways for Personalised & Oncology-Focused mRNA Therapies in a Framework Built for Vaccines**

- Understanding how personalised and patient-specific mRNA products are being approached by EMA and MHRA
- Learning from ongoing oncology-focused mRNA trials navigating the current patchwork of global expectations
- Discussing gaps in guidance for non-infectious mRNA indications and how companies are addressing them

Maren Von Fritschen
Head of Regulatory Policy Europe
Moderna

9.30 **Leveraging Regulatory Sandboxes & Platform Approaches to Accelerate Innovative mRNA Therapies from Concept to Clinic**

- Explore how regulatory sandbox models can provide early, flexible engagement with agencies to de-risk novel mRNA therapeutic development
- Understand how platform-based regulatory strategies can streamline approvals by leveraging prior data across multiple products
- Learn from emerging case studies on how these frameworks have reduced timelines, improved regulatory predictability, and enabled faster patient access

Ruben Rizzi
Senior Vice President
Global Regulatory Affairs, BioNTech

10.00 **Roundtable Discussion: Navigating the mRNA Regulatory Maze Across EMA FDA & MHRA to Accelerate Approval & Reduce Risk**

- Comparing how EMA, FDA, and MHRA currently define and assess mRNA-based therapeutics
- Understanding where regulatory definitions diverge (e.g., biologic vs. ATMP) and how to plan accordingly
- Learning how companies are building global regulatory strategies that reduce friction and misalignment

10.30 **Morning Break & Networking**

This networking session is your opportunity to get face-to-face with many of the brightest minds working in the mRNA field and establish meaningful business relationships to pursue for the rest of the conference

Kirsten Nespithal
Director Safety Lead Risk Management
BioNTech

11.30 **Comprehensive Safety Monitoring Across the mRNA Product Lifecycle from Clinical Development to Post-Marketing**

- Understand best practices of safety monitoring during clinical trials to ensure robust safety oversight
- Learn how post-marketing studies and close interaction with health authorities shape ongoing patient safety and regulatory compliance

Smarter mRNA Discovery & Development With AI-Powered Precision To Curate Real World Impact

Annie Sabbah
Chief Technology Officer
Barcode Nanotech

12.00 **Decoding Delivery: Machine Learning-Driven Optimization of RNA Therapeutics via Barcoded Nanoparticles**

- Explore how barcoded nanoparticles generate high-resolution datasets to map RNA delivery efficiency across tissues
- Learn how machine learning algorithms decode complex delivery patterns to optimise formulation design
- Understand how this approach accelerates the translation of RNA therapeutics with improved targeting and efficacy

Conference Day Two
Thursday 29th January, 2026

12.30 **Lunch & Networking**

13.30 **AI-Powered Precision: Accelerating Personalised Cancer Vaccine Development**

Prasun Chakraborty
Founder, Innovator & Chief Executive Officer
Genevation

- Accelerating neoantigen discovery: How AI integrates genomic, transcriptomic, and immunological data to rapidly identify and prioritise tumour-specific targets
- Optimising vaccine design: Using predictive models and adaptive strategies to anticipate immune response and iteratively refine personalised formulations
- Translating innovation into impact: Case studies where AI platforms have shortened development timelines, improved patient outcomes, and opened new horizons for immunotherapy

Shaping the Future of RNA Therapeutics With Next-Generation Modality Innovation to Advance Treatments Across Therapeutic Areas

14.00 NEW DATA **Unlocking the Therapeutic Power of Self-Amplifying & Circular RNA for Longer Expression and Lower Dosing**

Bo Ying
Chief Executive Officer
AboGen

- Discovering how saRNA and circRNA are redefining RNA's potential with longer-lasting expression, lower dosing, and expanded therapeutic applications
- Understanding the scientific and clinical implications of modality-specific challenges, from immunogenicity to delivery complexit
- Learning from pioneering case studies translating next-generation RNA formats into viable therapies across oncology, rare diseases, and beyond

14.30 **Afternoon Break & Networking**

15.00 **CycloPhore™ & SemaPhore™ Enabling Next-Generation Delivery Solutions for Circular RNA & mRNA therapeutics**

Covadonga Paneda
Chief Operating Officer
Altamira Therapeutics

- Explore how CycloPhore™ and SemaPhore™ overcome delivery barriers to enable the extrahepatic delivery of circular RNA and mRNA
- Understand the platform's potential for improving stability, targeting, and translational efficiency of RNA therapeutics
- Learn how patented delivery technologies are advancing the development of novel RNA modalities

15.30 NEW DATA **Harnessing Viral-Like Particles With Circular RNA to Boost Payload Expression Longevity**

Victor Levitsky
Chief Scientific Officer
Circio

- Explore how viral-like particles (VLPs) enable efficient delivery of large circular RNA constructs for gene expression
- Review preclinical data showing improved stability and expression outcomes compared to linear RNA formats
- Understand the translational potential of VLP–circRNA systems for advancing next-generation gene editing therapies

16.00 **Chair's Closing Remarks**

16.10 **End of Conference**

Where You Meet Your Next Partner

5th Annual mRNA-Based Therapeutics Summit EUROPE

27th – 29th January, 2026 | Berlin, Germany

Your Global Platform to Foster New & Existing Relationships Within the mRNA Field

The **5th mRNA-Based Therapeutics Summit Europe** is your platform to establish business relationships with 150+ biopharma, biotech, investors, and regulators. **Our audience isn't just attending to listen, they're here to find the partners who can help them solve their biggest challenges** as a new era of investment continues. Partner with us to capitalise on the novel research and contribute to the advancements of mRNA drugs while achieving your 2026 commercial goals.

What Do mRNA Drug Developers Need?

Raw Material Providers: Position yourself as the critical enabler of scalable, high-quality therapeutics by supporting the backbone of mRNA innovation.

RNA Synthesis & Manufacturing: Demonstrate how your services turn novel constructs into GMP-ready products that can advance confidently into the clinic.

Analytical & Assay Development: Highlight your tools for ensuring quality, potency, and stability — the checkpoints every therapy must pass before reaching patients.

Delivery & Formulation Experts: Showcase your cutting-edge LNPs, polymers, and targeted systems that are redefining what's possible in RNA delivery.

CDMOs: Reinforce your role as a trusted end-to-end partner, helping biotechs navigate complex CMC, scale-up, and regulatory demands with speed and reliability.

Seniority of Attendees



- C-Level/VP: 31%
- Director/Head: 40%
- Academics: 12%
- Scientist/ Team Leader: 13%
- Other: 4%

Type of Companies Attending



- Pharma / Biotech
- Service Providers
- Academic

*Statistics Taken from the 4th mRNA Based Therapeutics Summit Europe

Get Involved

Kiran Thompson
Senior Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

2026 Partners

5th Annual mRNA-Based Therapeutics Summit EUROPE
27th – 29th January, 2026 | Berlin, Germany

Lead Partner

Recipharm

Programme Partners

SARTORIUS

Vazyme™

Exhibition Partners

intertek

Roche

ELEGEN

"The support from the team helped us to address questions and achieve our commercial goals. I also enjoyed the speed networking. I got to network with people who I won't be able to interact with otherwise"

Past Sponsor, Marketing Strategies, Takara Bio

Get Involved

Kiran Thompson
Senior Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.mrnabased-therapeutics-europe.com/take-part/register/

+44 (0)20 3141 8700

info@hansonwade.com

Connect with leaders from **BioNTech**, **Ethris**, **AstraZeneca**, **Moderna**, **Eleven Therapeutics**, **Altamira Therapeutics**, and more to advance pipelines and forge lasting partnerships.

Harness practical case studies and strategies on scaling saRNA and circRNA, optimising LNP delivery, and rebuilding investor confidence post-COVID.

Collaborate with 150+ senior mRNA executives across **pharma**, **biotech**, **investment**, **and regulation** in a forum get actionable takeaways and accelerate innovation.

Drug Developers	Register & Pay by **Friday, 17th October**	Final Price
Conference + Focus Day	€ 2,897 **(Save €900)**	€ 3,797
Conference Only	€ 2,299 **(Save €500)**	€ 2,799

Academic & Research Institutes**	Register & Pay by **Friday, 17th October**	Final Price
Conference + Focus Day	€ 2,297 **(Save €900)**	€ 3,197
Conference Only	€ 1,899 **(Save €500)**	€ 2,399

Service Providers	Register & Pay by **Friday, 17th October**	Final Price
Conference + Focus Day	€ 3,797 **(Save €900)**	€ 4,697
Conference Only	€ 2,999 **(Save €500)**	€ 3,499

Please note: If you are a UK or EU-based company, you may be subject to 19% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hotel Palace Berlin
Budapester Str. 45, 10787 Berlin, Germany
www.palace.de/en/welcome

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom